Registry for patients with plasma cell disorders
Collection of Specimens and Clinical Data to Create A Bio-repository for the Multiple Myeloma Program: The Indiana Myeloma Registry
This study is collecting information and samples from people with plasma cell disorders like multiple myeloma to help improve future treatments and care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Indiana University Academic / other |
| Locations | 1 site (Indianapolis, Indiana) |
| Trial ID | NCT03616483 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect data and biological specimens from patients diagnosed with various plasma cell dyscrasias, including multiple myeloma and related conditions. It is a prospective, non-interventional study that will support future research efforts in understanding these diseases. Participants will be monitored over time to gather valuable information that can inform treatment and management strategies.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have been diagnosed with or are suspected to have conditions like multiple myeloma or monoclonal gammopathy.
Not a fit: Patients under 18 years of age or those without a diagnosis of the specified plasma cell disorders will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of plasma cell disorders and lead to improved treatment options for patients.
How similar studies have performed: Other observational studies in similar areas have shown success in collecting valuable data that has contributed to advancements in treatment and understanding of plasma cell disorders.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female patients ≥ 18 years of age at the time of informed consent 2. Has been diagnosed with or is suspected to have one of the following: 1. Monoclonal Gammopathy of Undetermined Significance (MGUS) 2. Smoldering Multiple Myeloma 3. Multiple Myeloma 4. Bony or Soft Tissue Plasmacytoma 5. Primary Amyloidosis Exclusion Criteria: \< 18 years of age Have not been diagnosed with one of the following: Monoclonal Gammopathy of Undetermined Significance (MGUS) b.Smoldering Multiple Myeloma c.Multiple Myeloma d.Bony or Soft Tissue Plasmacytoma e.Primary Amyloidosis
Where this trial is running
Indianapolis, Indiana
- Indiana University Simon Cancer Center — Indianapolis, Indiana, United States (Recruiting)
Study contacts
- Principal investigator: Attaya Suvannasankha, MD — Indiana University
- Study coordinator: Attaya Suvannasankha, MD
- Email: asuvanna@iu.edu
- Phone: 317-274-0843
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.